Analysis of heregulin symmetry by weighted evolutionary tracing.

Heregulins are members of the protein family of EGF-like growth and differentiation factors. The primary cell-surface targets of heregulins are heterodimers of the EGF-receptor homolog HER2 with either HER3 or HER4. We used a weighted evolutionary trace analysis to identify structural features that distinguish the EGF-like domain (hrg) of heregulins from other members of the EGF family. In this analysis, each amino acid sequence is weighted according to its uniqueness and the variability in each position is assigned by an amino acid substitution matrix. Conserved residues in heregulin that are variable in other EGF-like domains are considered possible specificity-conferring residues. This analysis identifies two clusters of residues at the foot of the boot-shaped hrg domain. The residues in one cluster are recruited from the N-terminus; those in the other are from the ohm-loop region and show a weak sequence similarity to the N-terminal residues at the opposite side of the boot. The remaining residues with high conservation scores distribute themselves into these two distinct surfaces on hrg. This pseudo-twofold symmetry and the presence of two distinct interfaces may reflect the preference of hrg for heterodimeric versus homodimeric HER complexes.

[1]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[2]  H. P. Fell,et al.  HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein (*) , 1995, The Journal of Biological Chemistry.

[3]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[4]  M. Sliwkowski,et al.  High-resolution solution structure of the EGF-like domain of heregulin-alpha. , 1996, Biochemistry.

[5]  D. Eisenberg,et al.  Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. , 1998, Biochemistry.

[6]  M. Waterfield,et al.  Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system , 1993, Nature.

[7]  P. Fedi,et al.  Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors , 1997, The EMBO journal.

[8]  R. Finn,et al.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells , 1997, Oncogene.

[9]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[10]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[12]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[13]  D. Kohda,et al.  Three-dimensional nuclear magnetic resonance structures of mouse epidermal growth factor in acidic and physiological pH solutions. , 1994, Biochemistry.

[14]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[15]  P. Argos,et al.  Weighting aligned protein or nucleic acid sequences to correct for unequal representation. , 1990, Journal of molecular biology.

[16]  F. Cohen,et al.  An evolutionary trace method defines binding surfaces common to protein families. , 1996, Journal of molecular biology.

[17]  M. Sliwkowski,et al.  Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis* , 1998, The Journal of Biological Chemistry.

[18]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Plowman,et al.  Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.

[20]  C. Sander,et al.  A method to predict functional residues in proteins , 1995, Nature Structural Biology.

[21]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[22]  M. Eisenstein,et al.  Bivalence of EGF‐like ligands drives the ErbB signaling network , 1997, The EMBO journal.

[23]  Y. Kan,et al.  Ligand-directed retroviral targeting of human breast cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[25]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Weber,et al.  Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases , 1997, Nature.

[27]  S A Benner,et al.  Amino acid substitution during functionally constrained divergent evolution of protein sequences. , 1994, Protein engineering.

[28]  M. Sliwkowski,et al.  Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Stroh,et al.  The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding (*) , 1995, The Journal of Biological Chemistry.

[30]  N. Taniguchi,et al.  A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. , 1997, Journal of biochemistry.